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AfricaThree siblings, aged 12, 4 and 2 years, presented at a Gambian clinicwith bone deformities. Radiographs of knees
and wrists conﬁrmed the presence of ﬂorid rickets. The family (including 2 unaffected siblings and the mother)
were investigated for hereditary rickets.
The three affected siblings had biochemical features of hereditary hypophosphataemic rickets with hypercalciuria
(HHRH) with normal plasma calcium and 25-hydroxyvitamin D concentrations, elevated 1,25-dihydroxyvitamin
D, hypophosphataemia, hyperphosphaturia and hypercalciuria. At presentation, two of the three affected siblings
had an elevated ﬁbroblast growth factor-23 (FGF23) concentration. The mother and clinically unaffected siblings
had largely normal biochemistry.
Genetic analysis of the SLC34A3 gene, encoding the type IIc sodium-phosphate cotransporter, in DNA samples
from the siblings and their mother was conducted. Three single nucleotide polymorphisms (SNPs) S168F,
E513V and L599L were identiﬁed. E513V and L599L had been previously identiﬁed as benign polymorphisms.
S168F however, is a previously unreported variant. In silico mutation evaluation predicted that the S168F muta-
tion causes changes in the protein product which are damaging to its function. In addition, the three clinically
affected siblings were homozygous in the S168F variant whereas the unaffected family members were carriers.
This study describes a biochemical proﬁle and complementary gene data consistent with a rare genetic
hypophosphataemic rickets disease in a family from rural Gambia. To our knowledge, this study reports
the ﬁrst cases of HHRH in Africa and describes a novel causal mutation within the SLC34A3 gene.
© 2012 Elsevier Inc. Open access under CC BY license.Introduction
Childrenwith putative dietary calcium deﬁciency rickets and chron-
ically elevated circulating ﬁbroblast growth factor-23 (FGF23), have
been reported in The Gambia [1]. It has been proposed that chronically
low dietary calcium (Ca) supply resulting in a 1,25-dihydroxyvitamin D
(1,25(OH)2D)-driven increase in FGF23 concentration and consequent
excessive urinary (u) phosphate (P) loss may be contributing to the
aetiology of this form of rickets [1,2].
During a study to assess the prevalence of rickets in The Gambia, a
family with apparent hereditary rickets was investigated [2]. Two
siblings (S5* and S2*) with the same mother and father presented at
a clinic in The Gambia with visible bone deformities and reported
bone pain. Radiographs conﬁrmed the presence of ﬂorid rickets. On
further investigation, an additional younger sibling (S1*) with boneamme numbers: U105960371 &
search, Elsie Widdowson Lab-
5.
uk (V. Braithwaite).
license.deformities was reported. Two other siblings (S3 and S4) were
clinically normal as was the mother. The family was investigated for
possible hereditary rickets, which revealed biochemical features of
hereditary hypophosphataemic rickets with hypercalciuria (HHRH)
in the three affected siblings (S5*, S2* and S1*). Mutations within
the SLC34AC gene are known to cause HHRH [3–5]. Subsequent
genotyping of the SLC34AC gene revealed a novel mutation which
was homozygous in the three affected siblings. The mother and the
other siblings were carriers for the same mutation.
This case series describes the biochemical proﬁle of the siblingswith
rickets and subsequent candidate gene analysis of the family members
(affected and unaffected) to establish aetiology. To our knowledge,
this study reports the ﬁrst cases of HHRH in Africa and describes a
novel causal mutation within the SLC34A3 gene.
Materials and methods
Subjects
Three siblings (S5* female, S2* male and S1* male) had bone defor-
mities (*) and were seen at a Gambian clinic on one or more occasions
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and the parents of the siblings showed no signs of bone deformities. A
family history revealed that, at the time, no-one else in the extended
family had bone deformities and that the parents were not close
relatives. However, it is possible that they are distantly related as con-
sanguinity is not uncommon in this population. Age-matched data
obtained from a community study, described in detail elsewhere [2],
provided contemporaneous local reference data for anthropometry
and biochemistry across appropriate age bands: 2.0–5.9 y (n=10),
6.0–9.9 y (n=10), 10.0–13.9 y (n=10), 14.0–17.9 y (n=10), and
18.0–47.0 y (n=52) (Table 1). Standard deviation scores (Z-scores)
were calculated for each variable for each subject using the
age-appropriate reference data in the following way:
value½ subject−mean½ references
Standard deviationreferences
:
Study approvals
Ethical approvals for the use of clinical notes and for the research
study were obtained from The Gambian Government/MRC Laborato-
ries Joint Ethics Committee. Written informed consent was obtained
from the family. The father did not participate in the study.
Clinical assessment and anthropometry
Adetailed clinical assessmentwas conducted to identify the presence
of any clinical signs and symptoms of rickets including; enlarged wrists
or ankles, leg pain, difﬁculty walking and bow-leg or windswept defor-
mity, and to discount other diseases associated with bone deformities.
Bilateral radiographs were taken of knees and wrists of the affected
children and were scored by a consultant paediatrician (JMP) using a
10-point scoring system developed by Thacher et al. [6]. Standard an-
thropometry was conducted which included weight (wt) and standing
height (ht).
Fasting blood and 2 h urine collection
An overnight-fasted, 2 h urine (u) sample was collected between
the hours of 07.00 and 09.00. Acidiﬁed (HCl 10 μL/mL, laboratory re-
agent grade SD 1.18, Fisher Scientiﬁc UK Ltd., Loughborough, UK)
urine aliquots were stored at−20 °C and then later transported frozen
on dry ice toMRCHuman Nutrition Research (HNR), Cambridge, UK for
analysis. A fasting, venous blood sample was collected, in the middle of
the 2 h urine collection, transferred to lithium heparin (LiHep) and
EDTA-coated tubes, plasma separated by centrifugation at 4 °C and fro-
zen at −20 °C, and later transported frozen on dry ice to MRC HNR,Table 1
Anthropometry and biochemical local reference data used to create age appropriate Z-sco
variables*.
Reference data in age
Variable 2.0–5.9 y
(n=10)
6.0–9.9 y
(n=10)
Ht (cm) 95.3 (10.3) 121.5 (9.8)
Wt (kg) 13.2 (2.6) 20.6 (3.6)
25OHD (nmol/L) 56.3 (18.9) 62.4 (14.7)
TALP (U/L) 299 (65) 325 (67)
1,25(OH)2D (pmol/L) 279 (64) 234 (48)
PTH*(pg/mL) 39 (24, 65) 40 (27, 58)
P (mmol/L) 1.59 (0.17) 1.57 (0.19)
Ca (mmol/L) 2.38 (0.08) 2.42 (0.08)
FGF23*(RU/mL) 83 (37, 188) 52 (31, 87)
TmP:GFR (mmol/L) 1.71 (0.27) 1.82 (0.26)
uCa:uCr*(mol/mol) 0.11 (0.03, 0.40) 0.08 (0.02, 0.27)where the plasma samples and the blood cell pellets were stored at−
80 °C until analysis.
Biochemical analysis
The plasma samples were analysed for markers of vitamin D, Ca and
P metabolism using commercially-available methods according to the
manufacturers' instructions: intact PTH (Immunoradiometric assay;
DiaSorin Ltd., Berks, UK), FGF23 (C-terminal ELISA; Immutopics Inc.,
CA, USA), 25OHD and 1,25(OH)2D (radioimmunoassay DiaSorin, MN,
USA and IDS, Tyne andWear, UK respectively). The following colorimet-
ric methods (Cobras Fara, Roche Products Ltd, UK and Konelab™
Analyser 20i, Finland) were used to determine plasma analytes: total
calcium (TCa) by methylthymol blue (Roche Unit-Kit II) and arsenazo
III (Konelab™ 981367); P, ammonium molybdate (Roche Unit-Kit II
and Konelab™ 981890); and total alkaline phosphatase (TALP),
p-nitrophenyl phosphate at 37 °C (Roche Alp MPR2 and Konelab™
981832). For FGF23, >125 RU/mL was used as an upper-limit cut-off
of normality. Acidiﬁed urine was used to determine urinary (u) uCa
and uP employing the same colorimetric methods as for plasma and
uCr was determined using the Jaffe method (Konelab™ 981832). uCa
excretion was expressed as a molar ratio with uCr. Tubular maximal
reabsorption of phosphate (TmP:GFR) (mmol/L) was determined in
the following way: Tubular reabsorption of phosphate (TRP)=1−
{(uP/P)×(Cr/uCr)}, if TRPb0.86 then TmP:GFR=TRP×P mmol/L, if
TRP>0.86 then TmP:GFR=(0.3×TRP/{1−(0.8×TRP)})×Pmmol/L [7].
Genetic analysis
The frozen EDTA blood pellets were sent to the Laboratory for Mo-
lecular Diagnostics, Centre of Nephrology and Metabolic Disorders,
Berlin, Germany for candidate gene analysis. DNA was extracted
using standard methodology (QIAamp DNA kit, Qiagen, West Sussex,
UK). Sequencing was performed using standard procedures with dye
terminators. The fragments were separated by capillary electrophore-
sis (ABI Prism 3130 genetic analyser, Hitachi Ltd., CA, USA). The candi-
date gene (SLC34A3)was sequenced in 12 fragments consisting of one
exon plus ~20 base pairs on either side of the exon in the youngest af-
fected sibling (S1*). All single nucleotide polymorphisms (SNPs) were
identiﬁed and the remaining siblings (n=4) and mother were then
screened for the variant SNPs. All SNPs were analysed using the NCBI
(National Center for Biotechnology Information) database according
to the GenBank transcript NM_080877.2. In silicomutation evaluation
to predict protein structure, was conducted using two programmes:
Mutation taster [8] and PolyPhen-2 [9]. Sequence alignment was
performed using the Basic Local Alignment Search Tool (BLAST®) on
the NCBI database.res. Data are presented as mean (SD) or geometric mean (−1SD, +1SD) for skewed
bands (mean SD)
10.0–13.9 y
(n=10)
14.0–17.9 y
(n=10)
18.0–47.0 y
(n=52)
146.6 (9.2) 156.6 (9.4) 158.9 (9.7)
34.5 (7.2) 42.9 (7.9) 58.7 (14.9)
55.4 (15.8) 48.3 (13.7) 63.9 (12.0)
298 (86) 298 (135) 125 (58)
254 (81) 263 (86) 241 (103)
53 (32, 88) 60 (39, 92) 59 (26, 134)
1.40 (0.19) 1.40 (0.22) 1.12 (0.18)
2.36 (0.09) 2.37 (0.09) 2.24 (0.14)
38 (23, 62) 45 (21, 96) 31 (19, 189)
1.64 (0.25) 1.63 (0.29) 1.17 (0.24)
0.09 (0.04, 0.22) 0.08 (0.02, 0.24) 0.07 (0.02, 0.22)
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Presentations
Case 1. Sibling 5* (S5*)
S5* (female) was the eldest of the ﬁve siblings and ﬁrst presented
with knock-knee deformity and bone pain at the age of 12 y in July
2000. She was short and light for her age relative to local age matched
children (Table 2). Biochemical analysis of a blood sample revealed
that she had concentrations of 25OHD and Ca within the normal
range, PTH was low with elevated concentrations of 1,25(OH)2D and
TALP. In addition she had low plasma P with a normal concentration
of FGF23. Urine analysis conﬁrmed a low TmP/GFR and hypercalciuria.
Radiographs conﬁrmed S5* to have active rickets with a Thacher score
of 4 and evidence of Looser zones and growth arrest lines.
Case 2. Sibling 2* (S2*)
S2* (male) presented with bow-leg deformity and bone pain at
the age of 2 y in May 2001. He was short for his age. As with S5*, he
had concentrations of 25OHD and Ca within the normal range, elevat-
ed concentrations of 1,25(OH)2D and TALP and low plasma P. Unlike
S5*, he had an elevated FGF23. PTH was not measured due to insufﬁ-
cient plasma sample. TmP/GFR was reduced and uCa:uCr increased.
Radiographs conﬁrmed S2* to have active rickets with a Thacher
score of 8.
Case 3. Sibling 1* (S1*)
S1* (male) was the youngest sibling (4 y) and ﬁrst presented with
bow-leg deformity in July 2006. Like S2*, he was short for his age, and
reported bone pain. Similar to S5* and S2* he had concentrations of
25OHD and Ca within the normal range, elevated concentrations of
TALP and low plasma P. Like S2*, he also had elevated FGF23. Neither
PTH nor 1,25(OH)2D was measured. Urine analyses conﬁrmed in-
creased renal P and Ca excretion. Radiographs conﬁrmed S1* to
have active rickets with a Thacher score of 7.Table 2
Biochemical data of affected (S5*, S2* and S1*) and unaffected (S3 and S4) siblings and the
Variable Affected subjects
S5* S2*
Age (y) 12a 18b 2a
Ht (cm) 120.4 129.0 86.5
(Z-Score) (−2.85) (−2.94) (−0.85)
Wt (kg) 29.5 46.6 13.7
(Z-Score) (−0.69) (0.47) (0.19)
25OHD (nmol/L) 56.0 58.7 36.6
(Z-Score) (0.02) (0.76) (−1.04)
TALP (U/L) 3291 294 689
(Z-Score) (35.00) (−0.03) (5.95)
1,25(OH)2D (pmol/L) 339 341 385
(Z-Score) (1.06) (0.91) (1.68)
PTH (pg/mL) 14.0 23.0 –
(Z-Score) (−2.66) (−2.29) –
P (mmol/L) 0.71 0.55 0.67
(Z-Score) (−3.57) (−3.89) (−5.49)
Ca (mmol/L) 2.46 2.33 2.39
(Z-Score) (1.08) (−0.22) (0.11)
FGF23 (RU/mL) 57.3 44.6 223.8
(Z-Score) (0.84) (−0.01) (1.21)
TmP:GFR (mmol/L) – 0.58 –
(Z-Score) – (−3.68) –
uCa:uCr (mol/mol) – 0.20 –
(Z-Score) – (0.85) –
Thacher X-ray score 4 F 8
a=ﬁrst presentation, b=off treatment follow-up, –=not determined, F=fused growth plaCharacterisation of unaffected siblings (S3 and S4) and mother
S3 (F), S4 (F) and the mother of the children were seen in July
2006 and were aged 11, 15 and 35 y respectively (the father did not
consent to examination or biochemical). They showed no clinical
bone deformities, but no radiographs were taken to conﬁrm this. S3
and S4 were both short and heavy for their ages. Their biochemical
proﬁles were largely normal, however, S4 had a lower than average
plasma P and TmP:GFR for her age, albeit not as low as her affected
siblings and both the mother and S3 had a higher than average uCa
excretion (uCa:uCr). No signs or symptoms of nephrocalcinosis
were reported in any of the siblings or the mother.
Treatment of S5* and S2*
Prior to the completion of the investigations, S5* and S2* were
treated with calcium and vitamin D with little or no clinical and ra-
diological responses although biochemically 25OHD and 1,25(OH)2D
concentrations did rise. Reviewing the results as a whole and espe-
cially the ﬁndings of a low TmP:GFR and high uCa:uCr, a tentative di-
agnosis of hereditary hypophosphataemic rickets with hypercalciuria
(HHRH) was made and the two siblings were started on oral phos-
phate therapy. Plasma P increased somewhat in S2* but little change
was seen in S5*. Problems with treatment compliance were acknowl-
edged and the therapy was subsequently terminated.
Gene sequencing and screening
Candidate gene analysis of the SLC34AC gene, encoding a type IIc
sodium-phosphate transporter (NaPi-IIc) expressed in the kidney, was
conducted in the DNA sample from the youngest affected sibling (S1*)
(Fig. 1). Three SNPs were found for which the other family members
were then screened. Two of the SNPs had been previously reported on
the NCBI database and had been assigned the following reference
numbers rs28542318 and rs74842953. These SNPs referred to a non-
synonymousmutation E513V (c.1538A>T) and a synonymousmutation
L599L (c.1795 T>C) respectively. In silico mutation analysis suggested
that these two SNPs were benign polymorphisms and they were uniqueir mother. Z-scores were calculated from age-matched data from the local community.
Unaffected subjects
S1 * S3 S4 Mother
7b 4a 11 15 35
106.1 87.1 128.5 146.8 154.7
(−1.57) (−0.79) (−1.97) (–1.04) (−0.43)
24.5 13.5 43.9 54.5 62.1
(1.08) (0.11) (1.30) (1.47) (0.22)
43.7 64.4 58.3 61.7 91.7
(−1.27) (0.43) (0.18) (0.98) (2.32)
1269 742 355 145 109
(14.10) (6.80) (0.66) (−1.13) (−0.26)
461 – 323 339 486
(4.67) – (0.86) (0.88) (2.37)
45.1 – 34.0 60.0 29.0
(0.28) – (−0.90) (−0.01) (−0.87)
0.42 0.53 1.30 1.00 1.12
(−5.75) (−6.33) (−0.51) (−1.84) (0.02)
2.40 2.42 2.44 2.39 2.09
(−0.26) (0.46) (0.86) (0.46) (−1.12)
64.9 629.9 54.5 32.9 33.5
(0.43) (2.49) (0.74) (−0.41) (−0.52)
0.50 0.63 1.58 1.20 1.27
(−5.03) (−4.00) (−0.23) (−1.52) (0.42)
0.38 1.05 0.32 0.15 0.22
(1.27) (1.76) (1.40) (0.59) (1.19)
10 7 – – –
te.
SNP SUBJECT
ID Amino Acid S1* S2* S3 S4 S5* M
unreported S168F- Damaging Homo Homo Hetero Hetero Homo Hetero
rs28542318 E513V-Benign Homo 0 0 0 0 0
rs74842953 L599L-Benign Homo 0 0 0 0 0
F Mo
S3S2*S2* S4 S5*
Fig. 1. Single-nucleotide polymorphisms (SNPs) on the SLC34A3 (NM_080877.2) gene in siblings (S1-5) and their mother (M). Subjects with rickets are indicated by * and are shad-
ed in black. Females are indicated by a circle and males by a square. Genetic analysis on the father (F) was not conducted. Homo=homozygous in the SNP, heterozygous=carriers
of the SNP, 0=no copy of the SNP.
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The third SNP was a novel non-synonymous mutation resulting in an
amino acid change S168F (c.503C>T). Blast alignment results indicated
that the ﬂanking amino acid regions at the site of the S168F mutation
were highly conserved throughout species (Table 3). In silico mutation
analysis predicted that this SNP would cause a damaging mutation in
the NaPi-IIc protein, the likely cause being the loss of function of the
transmembrane domain spanning 133–188 amino acids. Prediction anal-
ysis, suggested that the protein product containing S168F was of normal
length (599 amino acids) and that the correct reading frame was
maintained. The S168F mutation was present homozygously in the af-
fected siblings (S5*, S2* and S1*) and heterozygously in the unaffected
family members (Fig. 1).Discussion
The Republic of The Gambia (latitude 13°N) in West Africa has a
hot and dry tropical climate with a single wet season from June to
October. There is abundant UVB-containing sunshine throughout
the year and a lifestyle that does not limit skin UVB-exposure. Cases
of rickets have, however, been reported and have been attributed
predominantly to a chronically low dietary calcium (Ca) intake lead-
ing to a 1,25(OH)2D-driven increase in FGF23 leading to urinary
phosphate (P) wasting and rickets [1,2].
The family described in this study is, however, strikingly different to
our previous reports of rickets in The Gambia. To our knowledge, this
study documents the ﬁrst cases of hereditary hypophosphataemic
rickets with hypercalciuria (HHRH) in Africa. The cause of HHRH is a
mutation within the gene encoding the Type IIc sodium-phosphate
co-transporter [3,4]. There are twomajor NaPi co-transporters involved
in P reabsorption in the proximal tubule of the kidney. These are
NaPi-Type IIa and -Type IIc, both of which are regulated by FGF23 and
PTH. Although NaPi-IIa is thought to account for up to 70% of renal P
reabsorption [5], we show in this study that NaPi-IIc must also play an
integral role in P homeostasis. Additionally, we describe a novel muta-
tion in the SLC34AC gene.Table 3
Cross-species protein sequence alignment of ﬂanking regions of the S168F mutation
using BLAST®, NCBI database.
Species Protein sequence
S168F VPIIMGVNVGT F ITSTLVSMAQSGDRDEF  
[Homo sapien] VPIIMGVNVGT S ITSTLVSMAQSGDRDEF 
[Macaca mulatta] VPIIMGVNVGT S ITSTLVSMAQSGDRDEF 
[Pongo abelli] VPIIMGVNVGT S ITSTLVSMAQSGDRDEF 
[Mus muscullus] VPIIMGVNVGT S ITSTLVSMAQSGDRDEF 
[Cricetulus griseus] VPIIMGVNVGT S ITSTLVSMAQSGDRDEF 
[Bos taurus] VPIIMGVNVGT S ITSTLVSMAQSGDRDEF 
[Cavia porcellus] VPIIMGVNVGT S ITSTLVSMAQSGDRDEF 
[Callithrix jacchus] VPIIMGVNVGT S ITSTLVSMAQSGDRDEF 
[Rattus norvegicus] VPIIMGVNVGT S ITSTLVSMAQSGDRDEF 
[Heterocephalus glaber] VPIIMGVNVGT S ITSTLVSMAQSGDRDEF 
[Ailuropoda melanoleuca] VPIIMGVNVGT S ITSTLVSMAQSGDRDEF 
[Monodelphis domestica] VPIIMGVNVGT S ITSTLVSMAQSGARDEF 
[Canis lupus familiaris] VPIIMGVNVGT S ITSTLVSMAQSGDRDEFHHRH is associated with a distinct biochemical proﬁle resulting
from the loss of function of NaPi-IIc. This includes a reduction in P
reabsorption in the renal tubules leading to excessive urinary P loss.
A low TmP:GFR and plasma P are characteristic of this syndrome
which is often associated with an elevated 1,25(OH)2D and conse-
quent hypercalciuria. A raised FGF23 is not a distinguishing feature
of this syndrome, however we found elevated FGF23 at ﬁrst presenta-
tion with rickets in 2 out of 3 cases. This may be explained by a chron-
ically low dietary Ca intake and increased 1,25(OH)2D-driven
increase in FGF23 as described in the majority of Gambian nutritional
rickets [1]. Alternatively, this may have been due, in part, to the
young age of these children (b4 y) as we have previously seen that
FGF23 tends to decrease throughout childhood (unpublished data).
However the FGF23 Z-scores, calculated using local age-matched con-
trol children, were high at 2.5 and 1.2. It may also, however, be an in-
dicator of poor iron status leading to an increased expression of the
FGF23 gene and a subsequent increase in degradation of the intact
FGF23 hormone [10]. However, this possibility cannot be explored
in greater detail as the C-terminal assay and not the Intact FGF23
assay was used to measure FGF23 concentration in this study.
Some studies on HHRH cohorts, have shown that heterozygous
carriers of the mutation, although asymptomatic, may present with
hypercalciuria which puts them at a higher risk of developing
nephrocalcinosis [3]. We have shown that all investigated family mem-
bers had varying degrees of hypercalciuria with uCa:uCr values ranging
from 0.15 to 1.05 mol/mol. However, the presence or absence of
nephrocalcinosis could not be determined because of the lack of the
availability of renal ultrasound. Additionally, an interesting feature of
both the clinically affected and unaffected members of the family is
that they are consistently shorter and tended to be heavier than their
healthy yet undernourished peers. Thismaywell be a function of their fa-
milial environment, or perhaps an additional feature of the mutation.
A limitation of this study is that we have only described in silico pre-
dictions of the protein containing the novel S168F mutation, located
within a highly conserved region, leading to a loss of function of the
translated NaPi-IIc protein. Additional mutational analysis is required
to determine more detailed effects of this mutation on the protein func-
tion and the prevalence of the variant allele needs to be further explored
in the general Gambian population. Nevertheless, we have clearly shown
that the affected siblings were homozygous in the S168F mutation,
whereas the unaffected family members were carriers.
In summary, this study presents a novel mutation in the SLC34AC
gene causing HHRH. This is the ﬁrst kindred of HHRH to be reported
in Africa.
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